Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA:688443)
China · Delayed Price · Currency is CNY 29.36
-0.24 (-0.81%)
At close: Jan 21, 2026
SHA:688443 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
Net Income | -583.52 | -797.27 | -801.32 | -576.37 | -322.13 | -372.62 | Upgrade |
Depreciation & Amortization | 66.65 | 66.65 | 59.17 | 49.94 | 38.5 | 31.28 | Upgrade |
Other Amortization | 7.94 | 7.94 | 4.61 | 3.69 | 5.56 | 3.21 | Upgrade |
Loss (Gain) From Sale of Assets | 0 | 0 | - | -0 | - | -0 | Upgrade |
Asset Writedown & Restructuring Costs | 0.54 | 0.54 | 0 | 0 | 0.7 | 1.82 | Upgrade |
Loss (Gain) From Sale of Investments | -2.73 | -2.73 | -1.94 | -7.86 | -4.13 | -0.64 | Upgrade |
Provision & Write-off of Bad Debts | 0.63 | 0.63 | - | - | -0.03 | 0.03 | Upgrade |
Other Operating Activities | -22.93 | 29.51 | 34.01 | 33.99 | 32.15 | 34.41 | Upgrade |
Change in Accounts Receivable | -40.88 | -40.88 | 9.88 | -7.71 | -105.1 | 150.15 | Upgrade |
Change in Inventory | 4.69 | 4.69 | 1.85 | -22.67 | -17.81 | -4.66 | Upgrade |
Change in Accounts Payable | 1.73 | 1.73 | 51.1 | 55.87 | 131.8 | -124.26 | Upgrade |
Change in Other Net Operating Assets | 153.76 | 153.76 | 265.07 | 293.47 | 2.68 | 140.89 | Upgrade |
Operating Cash Flow | -414.12 | -575.44 | -377.58 | -177.64 | -237.82 | -140.39 | Upgrade |
Capital Expenditures | -65.91 | -45.32 | -90.98 | -146.21 | -112.7 | -56.4 | Upgrade |
Sale of Property, Plant & Equipment | 0.12 | 0.04 | - | - | 0 | - | Upgrade |
Investment in Securities | -485.47 | -382.28 | 211.6 | 194.2 | -409.24 | -0.35 | Upgrade |
Other Investing Activities | 5.93 | 0.14 | - | 3.4 | 1.12 | 0.44 | Upgrade |
Investing Cash Flow | -545.32 | -427.42 | 120.62 | 51.4 | -520.82 | -56.31 | Upgrade |
Short-Term Debt Issued | - | - | - | - | 73.32 | 219.7 | Upgrade |
Long-Term Debt Issued | - | 212.91 | 109.63 | 208.35 | 186.79 | 101.25 | Upgrade |
Total Debt Issued | 323.4 | 212.91 | 109.63 | 208.35 | 260.11 | 320.95 | Upgrade |
Short-Term Debt Repaid | - | - | - | - | -499.15 | -180.05 | Upgrade |
Long-Term Debt Repaid | - | -23.39 | -257.25 | -14.88 | -9.07 | -1.03 | Upgrade |
Total Debt Repaid | -45.53 | -23.39 | -257.25 | -14.88 | -508.22 | -181.08 | Upgrade |
Net Debt Issued (Repaid) | 277.87 | 189.52 | -147.62 | 193.48 | -248.11 | 139.87 | Upgrade |
Issuance of Common Stock | - | - | 3,308 | - | 1,000 | 150 | Upgrade |
Repurchase of Common Stock | -14.68 | -14.68 | - | - | - | - | Upgrade |
Common Dividends Paid | -30.28 | -28.67 | -35.02 | -32.1 | -21.59 | -14.22 | Upgrade |
Other Financing Activities | -8.42 | - | -25.41 | - | - | -44.77 | Upgrade |
Financing Cash Flow | 224.5 | 146.17 | 3,100 | 161.37 | 730.3 | 230.88 | Upgrade |
Net Cash Flow | -734.91 | -856.69 | 2,843 | 35.13 | -28.34 | 34.17 | Upgrade |
Free Cash Flow | -480.03 | -620.75 | -468.56 | -323.85 | -350.52 | -196.8 | Upgrade |
Free Cash Flow Margin | -213.19% | -2062.65% | -38675.98% | -68143.75% | -894.41% | -18092.66% | Upgrade |
Free Cash Flow Per Share | -1.31 | -1.69 | -1.46 | -1.18 | -1.27 | - | Upgrade |
Cash Income Tax Paid | 12.42 | 4 | -21.69 | -57.48 | -17.5 | -15.67 | Upgrade |
Levered Free Cash Flow | -222.78 | -413.65 | -267.97 | -190.87 | -715.31 | -87.28 | Upgrade |
Unlevered Free Cash Flow | -203.23 | -395.59 | -246.1 | -170.4 | -695.05 | -65.77 | Upgrade |
Change in Working Capital | 119.3 | 119.3 | 327.89 | 318.97 | 11.57 | 162.12 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.